Summary

Focal Segmental Glomerulosclerosis Market – Scope of Report
TMR’s report on the global focal segmental glomerulosclerosis market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global focal segmental glomerulosclerosis market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global focal segmental glomerulosclerosis market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the focal segmental glomerulosclerosis market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global focal segmental glomerulosclerosis market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global focal segmental glomerulosclerosis market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global focal segmental glomerulosclerosis market.

The report delves into the competitive landscape of the global focal segmental glomerulosclerosis market. Key players operating in the global focal segmental glomerulosclerosis market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global focal segmental glomerulosclerosis market profiled in this report.

Key Questions Answered in Global focal segmental glomerulosclerosis Market Report
• What is the sales/revenue generated by focal segmental glomerulosclerosis across all regions during the forecast period?
• What are the opportunities in the global focal segmental glomerulosclerosis market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Focal Segmental Glomerulosclerosis Market – Research Objectives and Research Approach
The comprehensive report on the global focal segmental glomerulosclerosis market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global focal segmental glomerulosclerosis market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global focal segmental glomerulosclerosis market.

ページTOPに戻る

Table of Contents

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Focal Segmental Glomerulosclerosis Market
4. Market Overview
4.1. Introduction
4.1.1. Disease Type Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Focal Segmental Glomerulosclerosis Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Disease Type/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Focal Segmental Glomerulosclerosis Market Analysis and Forecast, by Disease Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Disease Type, 2017–2031
6.3.1. Primary Focal Segmental Glomerulosclerosis
6.3.2. Secondary Focal Segmental Glomerulosclerosis
6.4. Market Attractiveness Analysis, by Disease Type
7. Global Focal Segmental Glomerulosclerosis Market Analysis and Forecast, by Disease Management
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Disease Management, 2017–2031
7.3.1. Diagnosis
7.3.1.1. Kidney Biopsy
7.3.1.2. Creatinine Test
7.3.1.3. Others
7.3.2. Treatment
7.3.2.1. Drug Therapy
7.3.2.2. Dialysis
7.3.2.3. Kidney Transplant
7.4. Market Attractiveness Analysis, by Disease Management
8. Global Focal Segmental Glomerulosclerosis Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region, 2017–2031
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Region
9. North America Focal Segmental Glomerulosclerosis Market Analysis and Forecast
9.1. Introduction
9.2. Key Findings
9.3. Market Value Forecast, by Disease Type, 2017–2031
9.3.1. Primary Focal Segmental Glomerulosclerosis
9.3.2. Secondary Focal Segmental Glomerulosclerosis
9.4. Market Value Forecast, by Disease Management, 2017–2031
9.4.1. Diagnosis
9.4.1.1. Kidney Biopsy
9.4.1.2. Creatinine Test
9.4.1.3. Others
9.4.2. Treatment
9.4.2.1. Drug Therapy
9.4.2.2. Dialysis
9.4.2.3. Kidney Transplant
9.5. Market Value Forecast, by Country, 2017–2031
9.5.1. U.S.
9.5.2. Canada
9.6. Market Attractiveness Analysis
9.6.1. By Disease Type
9.6.2. By Disease Management
9.6.3. By Country
10. Europe Focal Segmental Glomerulosclerosis Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Disease Type, 2017–2031
10.3.1. Primary Focal Segmental Glomerulosclerosis
10.3.2. Secondary Focal Segmental Glomerulosclerosis
10.4. Market Value Forecast, by Disease Management, 2017–2031
10.4.1. Diagnosis
10.4.1.1. Kidney Biopsy
10.4.1.2. Creatinine Test
10.4.1.3. Others
10.4.2. Treatment
10.4.2.1. Drug Therapy
10.4.2.2. Dialysis
10.4.2.3. Kidney Transplant
10.5. Market Value Forecast, by Country/Sub-region, 2017–2031
10.5.1. Germany
10.5.2. U.K.
10.5.3. France
10.5.4. Italy
10.5.5. Spain
10.5.6. Rest of Europe
10.6. Market Attractiveness Analysis
10.6.1. By Disease Type
10.6.2. By Disease Management
10.6.3. By Country/Sub-region
11. Asia Pacific Focal Segmental Glomerulosclerosis Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Disease Type, 2017–2031
11.3.1. Primary Focal Segmental Glomerulosclerosis
11.3.2. Secondary Focal Segmental Glomerulosclerosis
11.4. Market Value Forecast, by Disease Management, 2017–2031
11.4.1. Diagnosis
11.4.1.1. Kidney Biopsy
11.4.1.2. Creatinine Test
11.4.1.3. Others
11.4.2. Treatment
11.4.2.1. Drug Therapy
11.4.2.2. Dialysis
11.4.2.3. Kidney Transplant
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. China
11.5.2. Japan
11.5.3. India
11.5.4. Australia & New Zealand
11.5.5. Rest of Asia Pacific
11.6. Market Attractiveness Analysis
11.6.1. By Disease Type
11.6.2. By Disease Management
11.6.3. By Country/Sub-region
12. Latin America Focal Segmental Glomerulosclerosis Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Disease Type, 2017–2031
12.3.1. Primary Focal Segmental Glomerulosclerosis
12.3.2. Secondary Focal Segmental Glomerulosclerosis
12.4. Market Value Forecast, by Disease Management, 2017–2031
12.4.1. Diagnosis
12.4.1.1. Kidney Biopsy
12.4.1.2. Creatinine Test
12.4.1.3. Others
12.4.2. Treatment
12.4.2.1. Drug Therapy
12.4.2.2. Dialysis
12.4.2.3. Kidney Transplant
12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. Brazil
12.5.2. Mexico
12.5.3. Rest of Latin America
12.6. Market Attractiveness Analysis
12.6.1. By Disease Type
12.6.2. By Disease Management
12.6.3. By Country/Sub-region
13. Middle East & Africa Focal Segmental Glomerulosclerosis Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Disease Type, 2017–2031
13.3.1. Primary Focal Segmental Glomerulosclerosis
13.3.2. Secondary Focal Segmental Glomerulosclerosis
13.4. Market Value Forecast, by Disease Management, 2017–2031
13.4.1. Diagnosis
13.4.1.1. Kidney Biopsy
13.4.1.2. Creatinine Test
13.4.1.3. Others
13.4.2. Treatment
13.4.2.1. Drug Therapy
13.4.2.2. Dialysis
13.4.2.3. Kidney Transplant
13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. GCC Countries
13.5.2. South Africa
13.5.3. Rest of Middle East & Africa
13.6. Market Attractiveness Analysis
13.6.1. By Disease Type
13.6.2. By Disease Management
13.6.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
14.2. Market Share Analysis, by Company (2022)
14.3. Company Profiles
14.3.1. Variant Pharmaceuticals, Inc.
14.3.1.1. Company Overview
14.3.1.2. Disease Type Portfolio
14.3.1.3. SWOT Analysis
14.3.1.4. Financial Overview
14.3.1.5. Strategic Overview
14.3.2. ChemoCentryx, Inc.
14.3.2.1. Company Overview
14.3.2.2. Disease Type Portfolio
14.3.2.3. SWOT Analysis
14.3.2.4. Financial Overview
14.3.2.5. Strategic Overview
14.3.3. Travere Therapeutics
14.3.3.1. Company Overview
14.3.3.2. Disease Type Portfolio
14.3.3.3. SWOT Analysis
14.3.3.4. Financial Overview
14.3.3.5. Strategic Overview
14.3.4. AbbVie, Inc.
14.3.4.1. Company Overview
14.3.4.2. Disease Type Portfolio
14.3.4.3. SWOT Analysis
14.3.4.4. Financial Overview
14.3.4.5. Strategic Overview
14.3.5. Novartis AG
14.3.5.1. Company Overview
14.3.5.2. Disease Type Portfolio
14.3.5.3. SWOT Analysis
14.3.5.4. Financial Overview
14.3.5.5. Strategic Overview
14.3.6. Pfizer, Inc.
14.3.6.1. Company Overview
14.3.6.2. Disease Type Portfolio
14.3.6.3. SWOT Analysis
14.3.6.4. Financial Overview
14.3.6.5. Strategic Overview
14.3.7. AstraZeneca plc.
14.3.7.1. Company Overview
14.3.7.2. Disease Type Portfolio
14.3.7.3. SWOT Analysis
14.3.7.4. Financial Overview
14.3.7.5. Strategic Overview
14.3.8. Sanofi S.A.
14.3.8.1. Company Overview
14.3.8.2. Disease Type Portfolio
14.3.8.3. SWOT Analysis
14.3.8.4. Financial Overview
14.3.8.5. Strategic Overview
14.3.9. GlaxoSmithKline plc.
14.3.9.1. Company Overview
14.3.9.2. Disease Type Portfolio
14.3.9.3. SWOT Analysis
14.3.9.4. Financial Overview
14.3.9.5. Strategic Overview
14.3.10. Teva Pharmaceutical Industries Ltd.
14.3.10.1. Company Overview
14.3.10.2. Disease Type Portfolio
14.3.10.3. SWOT Analysis
14.3.10.4. Financial Overview
14.3.10.5. Strategic Overview